Skip to content

Study · Randomized controlled trial · n = 91 · 2005

8 results

Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.

Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K

Clinical rheumatology13 Jan 2005Cited by 21 (Europe PMC)

PMID15647969 (opens in a new tab)DOI10.1007/s10067-004-1004-6 (opens in a new tab)PepBankPUB-15647969
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with postmenopausal osteoporosis, calcitonin increased lumbar BMD by 3.0% from baseline and more than control.

    In plain wordsIn women with postmenopausal osteoporosis, calcitonin increased lower spine bone density more than control.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseLumbar BMD
    Study

    n = 91

    Comparator
    1alpha(OH)D3 and calcium without calcitonin
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU daily, 1 month on-1 month off · intranasal · 1 yearAs given in this study (human).

    Measurements

    Lumbar BMD change from baseline
    3%
    salmon calcitonin group

    Source sentences

    Summary
    Lumbar BMD increased significantly in the salmon calcitonin group from baseline (3.0%, p=0.005) and in comparison to the non-calcitonin-treated group (p=0.009).
    2 context sentences
    Summary · context
    A 1-year prospective, open, randomized, controlled trial was conducted as a pilot study to examine the effect of intermittent administration of 200 IU intranasal salmon calcitonin and 1alpha(OH) vitamin D3 [1alpha(OH)D3] on bone mineral density (BMD) of the lumbar spine and hip as well as on the mar…
    Summary · context
    A total of 91 patients completed the study (50 in the salmon calcitonin nasal spray group and 41 in the other group).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with postmenopausal osteoporosis, calcitonin increased femoral neck BMD by 3.1% from baseline and more than control.

    In plain wordsIn women with postmenopausal osteoporosis, calcitonin increased femoral neck bone density more than control.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseFemoral neck BMD
    Study

    n = 91

    Comparator
    1alpha(OH)D3 and calcium without calcitonin
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU daily, 1 month on-1 month off · intranasal · 1 yearAs given in this study (human).

    Measurements

    Femoral neck BMD change from baseline
    3.1%
    salmon calcitonin group

    Source sentences

    Summary
    The salmon calcitonin group also had a significant increase in femoral neck BMD compared with baseline values (3.1%, p=0.0005) and in comparison to the non-calcitonin-treated group (p=0.0005) in
    2 context sentences
    Summary · context
    A 1-year prospective, open, randomized, controlled trial was conducted as a pilot study to examine the effect of intermittent administration of 200 IU intranasal salmon calcitonin and 1alpha(OH) vitamin D3 [1alpha(OH)D3] on bone mineral density (BMD) of the lumbar spine and hip as well as on the mar…
    Summary · context
    A total of 91 patients completed the study (50 in the salmon calcitonin nasal spray group and 41 in the other group).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with postmenopausal osteoporosis, calcitonin increased Ward's triangle BMD by 2.9% from baseline and more than control.

    In plain wordsIn women with postmenopausal osteoporosis, calcitonin increased Ward's triangle bone density more than control.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseWard's triangle BMD
    Study

    n = 91

    Comparator
    1alpha(OH)D3 and calcium without calcitonin
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU daily, 1 month on-1 month off · intranasal · 1 yearAs given in this study (human).

    Measurements

    Ward's triangle BMD change from baseline
    2.9%
    salmon calcitonin group

    Source sentences

    Summary
    Ward's triangle BMD (2.9% from baseline values, p=0.009) and in comparison to the non-calcitonin-treated group (p=0.005)
    2 context sentences
    Summary · context
    A 1-year prospective, open, randomized, controlled trial was conducted as a pilot study to examine the effect of intermittent administration of 200 IU intranasal salmon calcitonin and 1alpha(OH) vitamin D3 [1alpha(OH)D3] on bone mineral density (BMD) of the lumbar spine and hip as well as on the mar…
    Summary · context
    A total of 91 patients completed the study (50 in the salmon calcitonin nasal spray group and 41 in the other group).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with postmenopausal osteoporosis, calcitonin increased trochanteric BMD by 3.4% from baseline and more than control.

    In plain wordsIn women with postmenopausal osteoporosis, calcitonin increased trochanteric bone density more than control.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseTrochanteric BMD
    Study

    n = 91

    Comparator
    1alpha(OH)D3 and calcium without calcitonin
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU daily, 1 month on-1 month off · intranasal · 1 yearAs given in this study (human).

    Measurements

    Trochanteric BMD change from baseline
    3.4%
    salmon calcitonin group

    Source sentences

    Summary
    trochanteric BMD (3.4% from baseline values, p=0.007) and in comparison to the non-calcitonin-treated group (P=0.01).
    2 context sentences
    Summary · context
    A 1-year prospective, open, randomized, controlled trial was conducted as a pilot study to examine the effect of intermittent administration of 200 IU intranasal salmon calcitonin and 1alpha(OH) vitamin D3 [1alpha(OH)D3] on bone mineral density (BMD) of the lumbar spine and hip as well as on the mar…
    Summary · context
    A total of 91 patients completed the study (50 in the salmon calcitonin nasal spray group and 41 in the other group).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with postmenopausal osteoporosis, calcitonin reduced serum iPTH by 2.5% from baseline and more than control.

    In plain wordsIn women with postmenopausal osteoporosis, calcitonin reduced parathyroid hormone more than control.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseSerum iPTH
    Study

    n = 91

    Comparator
    1alpha(OH)D3 and calcium without calcitonin
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU daily, 1 month on-1 month off · intranasal · 1 yearAs given in this study (human).

    Measurements

    Serum iPTH change from baseline
    −2.5%
    salmon calcitonin group

    Source sentences

    Summary
    In the same group, a significant decrease in iPTH serum levels compared to baseline values (-2.5%, p=0.005) and in comparison to the non-calcitonin-treated group (p=0.005) was noted.
    2 context sentences
    Summary · context
    A 1-year prospective, open, randomized, controlled trial was conducted as a pilot study to examine the effect of intermittent administration of 200 IU intranasal salmon calcitonin and 1alpha(OH) vitamin D3 [1alpha(OH)D3] on bone mineral density (BMD) of the lumbar spine and hip as well as on the mar…
    Summary · context
    A total of 91 patients completed the study (50 in the salmon calcitonin nasal spray group and 41 in the other group).
  6. 06HumanNon-randomized trialEfficacy outcome

    In women with postmenopausal osteoporosis, urinary Ca/creatinine fell 6.1% from baseline in the calcitonin group, which also received 1alpha(OH)D3 and calcium.

    In plain wordsIn women with osteoporosis given calcitonin nasal spray plus vitamin D and calcium, urinary calcium/creatinine fell 6.1% from baseline.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseUrinary Ca/creatinine
    Study

    n = 50

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU daily, 1 month on-1 month off · intranasal · 1 yearAs given in this study (human).

    Measurements

    Urinary Ca/creatinine change from baseline
    −6.1%
    salmon calcitonin group

    Source sentences

    Summary
    Urinary Ca/creatinine and Pyrilinks-D/creatinine levels were significantly decreased from baseline in the salmon calcitonin-treated group (-6.1 and -6.3%, respectively, p=0.001).
    2 context sentences
    Summary · context
    A 1-year prospective, open, randomized, controlled trial was conducted as a pilot study to examine the effect of intermittent administration of 200 IU intranasal salmon calcitonin and 1alpha(OH) vitamin D3 [1alpha(OH)D3] on bone mineral density (BMD) of the lumbar spine and hip as well as on the mar…
    Summary · context
    A total of 91 patients completed the study (50 in the salmon calcitonin nasal spray group and 41 in the other group).
  7. 07HumanNon-randomized trialEfficacy outcome

    In women with postmenopausal osteoporosis, urinary Pyrilinks-D/creatinine fell 6.3% from baseline in the calcitonin group, which also received 1alpha(OH)D3 and calcium.

    In plain wordsIn women with osteoporosis given calcitonin nasal spray plus vitamin D and calcium, urinary Pyrilinks-D/creatinine fell 6.3% from baseline.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseUrinary Pyrilinks-D/creatinine
    Study

    n = 50

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU daily, 1 month on-1 month off · intranasal · 1 yearAs given in this study (human).

    Measurements

    Urinary Pyrilinks-D/creatinine change from baseline
    −6.3%
    salmon calcitonin group

    Source sentences

    Summary
    Urinary Ca/creatinine and Pyrilinks-D/creatinine levels were significantly decreased from baseline in the salmon calcitonin-treated group (-6.1 and -6.3%, respectively, p=0.001).
    2 context sentences
    Summary · context
    A 1-year prospective, open, randomized, controlled trial was conducted as a pilot study to examine the effect of intermittent administration of 200 IU intranasal salmon calcitonin and 1alpha(OH) vitamin D3 [1alpha(OH)D3] on bone mineral density (BMD) of the lumbar spine and hip as well as on the mar…
    Summary · context
    A total of 91 patients completed the study (50 in the salmon calcitonin nasal spray group and 41 in the other group).
  8. 08HumanNon-randomized trialEfficacy outcome

    In women with postmenopausal osteoporosis, bone-specific alkaline phosphatase fell 3.6% from baseline in the calcitonin group, which also received 1alpha(OH)D3 and calcium.

    In plain wordsIn women with osteoporosis given calcitonin nasal spray plus vitamin D and calcium, bone-specific alkaline phosphatase fell 3.6% from baseline.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseBone-specific alkaline phosphatase
    Study

    n = 50

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU daily, 1 month on-1 month off · intranasal · 1 yearAs given in this study (human).

    Measurements

    Bone-specific alkaline phosphatase change from baseline
    −3.6%
    salmon calcitonin group

    Source sentences

    Summary
    Bone-specific alkaline phosphatase levels were also significantly decreased from baseline in the salmon calcitonin-treated group (-3.6%, p=0.003).
    2 context sentences
    Summary · context
    A 1-year prospective, open, randomized, controlled trial was conducted as a pilot study to examine the effect of intermittent administration of 200 IU intranasal salmon calcitonin and 1alpha(OH) vitamin D3 [1alpha(OH)D3] on bone mineral density (BMD) of the lumbar spine and hip as well as on the mar…
    Summary · context
    A total of 91 patients completed the study (50 in the salmon calcitonin nasal spray group and 41 in the other group).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.